New Perspectives in the Drug Treatment of Kawasaki Disease
- 17 Downloads
Kawasaki disease (KD) has become the leading cause of acquired heart disease in developed countries. Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose). Therapy administered within the first 10 days of the onset of the illness has been shown to reduce arterial wall inflammation and thereby prevent the development of coronary artery aneurysm formation.
The majority of patients with KD will respond to conventional therapy. However, the management of nonresponders and patients with complications (such as acute thrombosis and chronic coronary artery changes) remains controversial. In this review article, we address some of these controversies and also describe newer treatment modalities that have been used in the management of patients with KD, both in the acute and convalescent stages of the disease.
KeywordsAspirin Adis International Limited Kawasaki Disease Dipyridamole Coronary Artery Aneurysm
Unable to display preview. Download preview PDF.
- 1.Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Jpn J Allergy 1967; 16: 178–222Google Scholar
- 2.Rose V. Kawasaki syndrome: cardiovascular manifestations. J Rheumatol 1990; 17Suppl. 24: 11–4Google Scholar
- 16.Lee JH, Hung HY, Huang FY Kawasaki disease with Reye syndrome: report of one case. Chung-Hua Min Kuo Hsiao Erh Ko I Hseuh Hui Tsa Chih 1992; 33(1): 67–71Google Scholar
- 24.Kan Z, Hoshino K, Ogawa K, et al. Steroid-aspirin combination therapy for treatment of Kawasaki disease [in Japanese]. J Pediatr Pract 1990; 53: 328–31Google Scholar
- 26.Takahashi K, Naoe S, Oharaseki T, et al. Autopsy cases of Kawasaki disease with ruptured coronary aneurysms. 6th International Kawasaki Disease Symposium; 1999 Feb 11–14; Waikoloa, HawaiiGoogle Scholar